Managing sarcoma: where have we come from and where are we going?

@inproceedings{Bleloch2017ManagingSW,
  title={Managing sarcoma: where have we come from and where are we going?},
  author={Jenna S. Bleloch and Reyna Deeya Ballim and Serah Kimani and Jeannette Parkes and Eugenio Panieri and Tarryn Willmer and Sharon J Prince},
  booktitle={Therapeutic advances in medical oncology},
  year={2017}
}
Sarcomas are a heterogeneous group of neoplasms of mesenchymal origin. Approximately 80% arise from soft tissue and 20% originate from bone. To date more than 100 sarcoma subtypes have been identified and they vary in molecular characteristics, pathology, clinical presentation and response to treatment. While sarcomas represent <1% of adult cancers, they account for approximately 21% of paediatric malignancies and thus pose some of the greatest risks of mortality and morbidity in children and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 242 references

Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial

GD Demetri, M von Mehren, RL Jones
J Clin Oncol • 2016